Prolor Biotech (PBTH) is due to present preclinical data tomorrow providing further evidence that its Factor VIIa-CTP hemophilia therapy can be administered with an injection as well as intravenously. Providing the clotting agent via an injection would facilitate its prophylactic use by patients as a way to prevent bleeding rather than just for when a bleeding episode occurs. Prolor Biotech hopes to start two clinical trials for the treatment next year. (PR)
Prolor Biotech (PBTH) is due to present preclinical data tomorrow providing further evidence...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs